Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Dublin, Nov. 16, 2023 (GLOBE NEWSWIRE) -- The "Hematology Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.Hematology Collaboration and...
-
Dublin, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The "Global Chemotherapy-Induced Anemia Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global chemotherapy-induced...
-
SAN FRANCISCO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2023 financial results on Monday, November 6 after the market close. FibroGen will also...
-
Selbyville, Delaware, Sept. 10, 2023 (GLOBE NEWSWIRE) -- Sickle Cell Disease Treatment Market size is expected to be worth USD 7.79 billion by 2032. SCD is a genetic disorder that affects millions...
-
Dublin, Aug. 21, 2023 (GLOBE NEWSWIRE) -- The "Global Sickle Cell Anemia Testing & Screening Market by Technology, Age Group, Sector - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and...
-
Akebia’s Vafseo (vadadustat) Poised to Make Waves for GSK’s Jesduvroq and FibroGen/Astellas’ Evrenzo
Exton, Pennsylvania, July 20, 2023 (GLOBE NEWSWIRE) -- Nephrologists have long awaited the approval of HIF-PH inhibitors for the treatment of anemia in their chronic kidney disease (CKD) patients....
-
Dublin, June 21, 2023 (GLOBE NEWSWIRE) -- The "Hematology Analyzer Market" report has been added to ResearchAndMarkets.com's offering.The global market for hematology analyzers was valued at $3.8...
-
DUBLIN, Feb. 11, 2023 (GLOBE NEWSWIRE) -- Nemysis is pleased to announce the publication of the successful findings from the IHAT-Gut trial in iron-deficient anaemic patients (NCT02941081) in the...
-
Continued advancement of pamrevlumab clinical trials – topline data from five pivotal Phase 3 trials beginning in 1H 2023 through mid-2024Completed enrollment of MATTERHORN Phase 3 study of roxadustat...
-
SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Stifel 2022...